Neoplastic diseases remain one of the paramount challenges in contemporary medicine, as their intrinsic heterogeneity and adaptive plasticity significantly hinder long-term therapeutic success. While the development of novel pharmacological agents targeting specific molecular drivers has advanced the therapeutic landscape, monotherapy approaches often fail to achieve durable disease control due to the emergence of resistance-conferring mutations. This necessitates an in-depth investigation of tumor heterogeneity and its dynamic response to therapeutic pressures through next-generation sequencing (NGS), which enable longitudinal monitoring of disease evolution. Concurrently, the paradigm shift toward combination therapies has demonstrated superior clinical efficacy compared to single-agent treatments, leveraging synergistic mechanisms to overcome resistance. However, these approaches frequently precipitate towards adverse events and intolerability, ultimately compromising therapeutic adherence and outcomes. In this context, the advent of cutting-edge drug delivery technologies has revolutionized oncological treatment strategies, offering unprecedented precision in drug targeting. Engineered nanoparticles facilitate the controlled and localized release of therapeutic agents within the tumor microenvironment or internal citosol of neoplastic cell thereby mitigating systemic toxicity while enhancing bioavailability. Moreover, these sophisticated delivery systems overcome physiological barriers, including hypoxia and a dense extracellular matrix, thereby augmenting drug penetration. These engineered carriers enable the inclusion of patients harboring resistance mutations by allowing the co-delivery of multiple targeted agents directly to the neoplastic site, thereby expanding therapeutic eligibility and efficacy. In conclusion it seems that nanotechnology potentialities promisingly support the exploration of the future horizons of new era of precision oncology 2.0 whose most urgent need is the administration of multiple drugs.
Technological progress and smart therapies: two sides of the same coin
Pasqua L.;Catalano S.
2025-01-01
Abstract
Neoplastic diseases remain one of the paramount challenges in contemporary medicine, as their intrinsic heterogeneity and adaptive plasticity significantly hinder long-term therapeutic success. While the development of novel pharmacological agents targeting specific molecular drivers has advanced the therapeutic landscape, monotherapy approaches often fail to achieve durable disease control due to the emergence of resistance-conferring mutations. This necessitates an in-depth investigation of tumor heterogeneity and its dynamic response to therapeutic pressures through next-generation sequencing (NGS), which enable longitudinal monitoring of disease evolution. Concurrently, the paradigm shift toward combination therapies has demonstrated superior clinical efficacy compared to single-agent treatments, leveraging synergistic mechanisms to overcome resistance. However, these approaches frequently precipitate towards adverse events and intolerability, ultimately compromising therapeutic adherence and outcomes. In this context, the advent of cutting-edge drug delivery technologies has revolutionized oncological treatment strategies, offering unprecedented precision in drug targeting. Engineered nanoparticles facilitate the controlled and localized release of therapeutic agents within the tumor microenvironment or internal citosol of neoplastic cell thereby mitigating systemic toxicity while enhancing bioavailability. Moreover, these sophisticated delivery systems overcome physiological barriers, including hypoxia and a dense extracellular matrix, thereby augmenting drug penetration. These engineered carriers enable the inclusion of patients harboring resistance mutations by allowing the co-delivery of multiple targeted agents directly to the neoplastic site, thereby expanding therapeutic eligibility and efficacy. In conclusion it seems that nanotechnology potentialities promisingly support the exploration of the future horizons of new era of precision oncology 2.0 whose most urgent need is the administration of multiple drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
